Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab
Sponsor: GlaxoSmithKline